Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter

Molecular and Cellular Biology

Volumn 15, Issue 12, 1995, Pages 6785-6793

  Shivakumar, Chittari V ^a   Brown, Doris R ^a   Deb, Sumitra ^a   Deb, Swati Palit ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; MUTANT PROTEIN; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; DNA REPAIR; ETIOLOGY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; VERO CELL;

ANIMALIA;

EID: 0028868432     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.15.12.6785     Document Type: Article

References (86)

1. Agoff, S. N., J. Hou, D. I. H. Linzer, and B. Wu. 1993. Regulation of the human hsp70 promoter by p53. Science 259:84-87.
2. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461-468.
3. Bargonetti, J., P. N. Friedman, S. E. Kern, B. Vogelstein, and C. Prives. 1991. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083-1091.
4. Borellini, F., and R. Glazer. 1993. Induction of Spl-p53 DNA-binding heterocomplexcs during granulocyte/macrophage colony-stimulating factor dependent proliferation in human erythroleukemia cell line TF-1. J. Biol. Chem. 268:7923-7928.
5. Brown, D. R., S. Deb, R. M. Muñoz, M. A. Subler, and S. P. Deb. 1993. The tumor suppressor p53 and the viral oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol. Cell. Biol. 13: 6849-6857.
6. Celis, J. E., and P. Madsen. 1986. Increased nuclear cyclin/PCNA antigen staining of non S-phase transformed human amnion cells engaged in nucleotide excision DNA repair. FEBS Lett. 209:277-283.
7. Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107-4114.
8. Chen, X., G. Farmer, H. Zhu, R. Prywes, and C. Prives. 1993. Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism of transcriptional activation. Genes Dev. 7:1837-1849.
9. Chin, K.-V., K. Ueda, I. Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462.
10. Cho, Y., S. Gorina, P. D. Jeffery, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
11. Dameron, K. M., O. V. Volpert, M. A. Tainsky, and N. Bouck. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Nature (London) 265:1582-1584.
12. Deb, S. Unpublished data.
13. Deb, S., D. R. Brown, H. Lega, and S. P. Deb. 1995. Transcriptional antagonism between p53 and SV40 T antigen. Int. J. Oncol. 6:243-249.
14. Deb, S., C. T. Jackson, M. A. Subler, and D. W. Martin. 1992. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J. Virol. 66:6164-6170.
15. Deb, S. P., R. M. Muñoz, D. R. Brown, M. A. Subler, and S. Deb. 1994. Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9:1341-1350.
16. Diller, L., J. Kassel, C. E. Nelsom, M. A. Gryka, G. Litwake, M. Gebhardt, B. Bressac, M. Ozturk, S. Baker, B. Vogelstein, and S. H. Friend. 1990. p53 functions as a cell cycle protein in osteosarcomas. Mol. Cell. Biol. 10:5772-5781.
17. Dittmer, D., S. Pati, G. Zambetti, S. Chu, A. Teresky, M. Moore, C. Finlay, and A. J. Levine. 1993. Gain of function mutations in p53. Nat. Genet. 4:42-46.
18. Donehower, L. A., and A. Bradley. 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155:185-205.
19. El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
20. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, D. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
21. Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature (London) 358: 83-86.
22. Fields, S., and S. K. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049.
23. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866-2871.
24. Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl, Acad. Sci. USA 88:9979-9983.
25. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
26. Greenblat, M. S., W. P. Bennet, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
27. Hall, P. A., P. H. Mckee, H. Menage, R. Dover, and D. P. Lane. 1993. High levels of p53 protein in UV-irradiated normal skin. Oncogene 8:203-207.
28. Hinds, P. W., C. A. Finlay, R. S. Quartin, S. J. Baker, E. R. Fearon, B. Vogelstein, and A. J. Levine. 1990. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spots" mutated phenotypes. Cell Growth Differ. 1:571-580.
29. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancer. Science 253:49-53.
30. Horikoshi, N., A. Usheva, J. Chen, A. J. Levine, R. Weinmann, and T. Shenk. 1995. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol. 15:227-234.
31. Jackson, P., P. Ridgway, J. Rayner, J. Noble, and A. Braithwaite. 1994. Transcriptional regulation of the PCNA promoter by p53. Biochem. Biophys. Res. Commun. 203:133-140.
32. Kastan, M. B., O. Zhan, W. S. El-Diery, F. Carrier, T. Jacks, W. F. Walsh, B. S. Pluckett, B. Vogelstein, and A. J. Florence. 1992. Participation of p53 protein in the cellular response to DNA damage. Cell 71:587-597.
33. Kern, S. E., K. W. Kinzler, S. J. Baker, J. M. Nigro, V. Rotter, A. J. Levine, P. Friedman, C. Prives, and B. Vogelstein. 1991. Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 6:131-136.
34. Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jaosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711.
35. Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
36. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild type p53 is a cell cycle check point determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
37. Lane, D. P. 1994. p53 and human cancers. Br. Med. Bull. 50:582-599.
38. Lechner, M. S., D. H. Mack, A. B. Fincle, T. Crook, K. H. Vousden, and L. A. Laiminis. 1992. Human papilloma virus E6 proteins bind p53 in vivo and abrogate p53 mediated repression of transcription. EMBO J. 11:3045-3052.
39. Leng, P., D. R. Brown, C. V. Shivakumar, S. Deb, and S. P. Deb. 1995. N-terminal 154 amino acids of mdm2 are sufficient to inhibit p53 mediated transcriptional activation. Oncogene 10:1275-1282.
40. Levine, A. J. 1993. The tumor suppressor genes. Annu. Rev. Biochem. 62:623-651.
41. Levine, A. J., J. Momand, and C. A. Finlay. 1991. The p53 tumor suppressor gene. Nature (London) 351:453-456.
42. Li, R., S. Waga, G. R. Hannon, D. Beach, and B. Stillman. 1994. Differential effects by the p21 CDK inhibitor on PCNA-dependent replication and repair. Nature (London) 371:534-537.
43. Lin, D., M. Shields, S. Ulrich, E. Appella, and W. Mercer. 1992. Growth arrest induced by wild type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl. Acad. Sci. USA 89:9210-9214.
44. Liu, X., C. W. Miller, P. H. Koeffler, and A. J. Berk. 1993. The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13:3291-3300.
45. Lu, X., and D. P. Lane. 1993. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75:765-778.
46. Mack, D. H., J. Vartikar, J. M. Pipas, and L. A. Laiminis. 1994. Specific repression of TATA mediated but not initiator mediated transcription by wild type p53. Nature (London) 363:281-283.
47. Martin, D. W., R. M. Muñoz, M. A. Subler, and S. Deb. 1993. p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem. 268:13062-13067.
48. Mercer, W. E., M. T. Shields, D. Lin, E. Appella, and S. J. Ullrich. 1991. Growth suppression induced by wild type p53 protein is accompanied by selective down regulation of proliferating cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA 88:1958-1962.
49. Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013-5020.
50. Milner, J., and E. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774.
51. Miyashita, T., S. Krajewska, M. Krejewska, H. G. Wang, H. K. Lin, D. A. Libermann, B. Hoffmann, and J. C. Reed. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805.
52. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
53. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237-1245.
54. Morris, G. F., and M. B. Mathews. 1990. Analysis of the proliferating cell nuclear antigen promoter and its response to adenovirus early region I. J. Biol. Chem. 265:16116-16125.
55. Okamoto, K., and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13:4816-4822.
56. Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature (London) 358:80-83.
57. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1992. Oncoprotein mdm2 conceals the activation domain of tumor suppressor p53. Nature (London) 362:857-860.
58. O'Rourke, R. W., C. W. Miller, G. J. Kato, K. J. Simon, D.-L. Chen, C. V. Dang, and H. P. Koeffler. 1990. A potential transcriptional activation element in the p53 protein. Oncogene 5:1829-1832.
59. Paveletich, N. P., K. A. Chambers, and C. O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:2556-2564.
60. Prives, C. 1994. How loops, B sheets, and helices help us to understand p53. Cell 78:543-546.
61. Ragimov, N., A. Krauskopf, N. Navot, V. Rotter, M. Oren, and Y. Aloni. 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8:1183-1193.
62. Raycroft, L., H. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051.
63. Sabbatini, P., S.-K. Chio, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15:1060-1070.
64. Santhanam, V., A. Ray, and P. Sehgal. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA 88:7605-7609.
65. Scheffener, M., K. Mungner, J. C. Byrne, and P. M. Howley. 1991. The state of p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88:5523-5527.
66. Scheffener, M., J. M. Werness, J. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
67. Seto, E., A. Usheva, G. P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89:12028-12032.
68. Shen, Y., and T. Shenk. 1994. Relief of p53 mediated transcriptional repression by the adenovirus EIB 19 KDA protein or the cellular Bcl-2 protein. Proc. Natl. Acad. Sci. USA 91:8940-8944.
69. Shivji, M. K. K., M. K. Kenny, and R. D. Wood. 1992. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69:367-374.
70. Smith, M. L., T. I. Chen, Q. Zhan, I. Bae, C. Y. Chen, T. M. Gilmer, M. B. Kastan, P. M. O'Connor, and A. J. Forance, Jr. 1994. Interaction of the p53 regulated protein GADD45 with proliferating cell nuclear antigen. Science 266:1376-1380.
71. Subler, M. A., and S. Deb. Unpublished data.
72. Subler, M. A., D. W. Martin, and S. Deb. 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66:4757-4762.
73. Subler, M. A., D. W. Martin, and S. Deb. 1994. Overlapping domains on the p53 protein regulate its transcriptional activation and repression function. Oncogene 9:1351-1359.
74. Thut, C., J. L. Chen, R. Klemm, and R. Tjian. 1995. p53 transcriptional activation mediated by co activators TAFII40 and TAFII60. Science 267: 100-104.
75. Toschi, L., and R. Bravo. 1988. Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J. Cell Biol. 107:1623-1628.
76. Truant, R., H. Xiao, C. J. Ingles, and J. Greenblatt. 1993. Direct interaction between the transcriptional activation domain of human p53 and the TATA-binding protein. J. Biol. Chem. 268:2284-2287.
77. Tsutsumi-Ishi, Y., K. Tadokoro, F. Hanaoka, and N. Tsuchida. 1995. Response of heat shock element within the human HSP70 promoter to mutated genes. Cell Growth Differ. 6:1-8.
78. Unger, T., M. M. Nau, S. Segal, and J. D. Minna. 1992. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11:1383-1390.
79. Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523-526.
80. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (London) 369:574-578.
81. Waga, S., and B. Stillman. 1994. Anatomy of a DNA replication fork revealed by reconstitution of SV40 DNA replication in vitro. Nature (London) 369:207-212.
82. Wang, W., and J. D. Gralla. 1991. Differential ability of proximal and remote element pairs to cooperate in activating RNA polymerase II transcription. Mol. Cell. Biol. 11:4561-4571.
83. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:2575-2586.
84. Xiao, H., A. Pearson, B. Coulombe, R. Traunt, S. Zhang, J. L. Regier, S. J. Triezenberg, D. Reinberg, O. Flores, C. J. Ingles, and J. Greenblatt. 1994. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol. Cell. Biol. 14:7013-7024.
85. Zambetti, G. P., J. Bargonetti, K. Walker, C. Prives, and A. J. Levine. 1992. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6:1143-1152.
86. Zastawny, R. L., R. Salvino, J. Chin, S. Benchimol, and V. Ling. 1993. The core promoter region of the p-glycoprotein gene is sufficient to confer differential responsiveness to wild type and mutant p53. Oncogene 8:1529-1535.